Colleen Silk/LinkedIn
Nov 4, 2025, 08:22
Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”Rare diseases remind us that science must never overlook the few.
Hemophilia B with inhibitors affects only a small number of people, yet its impact is profound.
We are proud to have been recognized as a finalist for the 2025 Prix Galien US Award for Best Orphan/Rare Disease Product.
Novo Nordisk believes that every person—no matter how rare their condition—deserves the best that science can offer.
We’re proud of this recognition and grateful to the Prix Galien Foundation for honoring innovation that makes a real difference.”
More winner stories featured in Hemostasis Today.
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial